Journal
GENETICS IN MEDICINE
Volume 24, Issue 2, Pages 374-383Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.gim.2021.09.018
Keywords
Adrenocortical tumors; ARMC5; Cushing syndrome; GIPR; KDM1A
Categories
Ask authors/readers for more resources
This study identified KDM1A gene inactivation as the cause of food-dependent Cushing syndrome (FDCS) in 90% of primary bilateral macronodular adrenal hyperplasia (PBMAH) cases. Through multiomics analysis of patient tissues, the study classified patients into different molecular groups and suggested genetic screening for ARMC5 and KDM1A for earlier diagnosis and improved management.
Purpose: This study aimed to investigate the genetic cause of food-dependent Cushing syndrome (FDCS) observed in patients with primary bilateral macronodular adrenal hyperplasia (PBMAH) and adrenal ectopic expression of the glucose-dependent insulinotropic polypeptide receptor. Germline ARMC5 alterations have been reported in about 25% of PBMAH index cases but are absent in patients with FDCS. Methods: A multiomics analysis of PBMAH tissues from 36 patients treated by adrenalectomy was performed (RNA sequencing, single-nucleotide variant array, methylome, miRNome, exome sequencing). Results: The integrative analysis revealed 3 molecular groups with different clinical features, namely G1, comprising 16 patients with ARMC5 inactivating variants; G2, comprising 6 patients with FDCS with glucose-dependent insulinotropic polypeptide receptor ectopic expression; and G3, comprising 14 patients with a less severe phenotype. Exome sequencing revealed germline truncating variants of KDM1A in 5 G2 patients, constantly associated with a somatic loss of the KDM1A wild-type allele on 1p, leading to a loss of KDM1A expression both at messenger RNA and protein levels (P = 1.2 x 10(-12) and P < .01, respectively). Subsequently, KDM1A pathogenic variants were identified in 4 of 4 additional index cases with FDCS. Conclusion: KDM1A inactivation explains about 90% of FDCS PBMAH. Genetic screening for ARMC5 and KDM1A can now be offered for most PBMAH operated patients and their families, opening the way to earlier diagnosis and improved management. (C) 2021 by American College of Medical Genetics and Genomics. Published by Elsevier Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available